NCT05279235.

Study name	Efficacy and safety of JT001 (VV116) compared with favipiravir
Methods	Double‐blinded, randomized, phase III
Participants	People with moderate to severe COVID‐19
Interventions	JT001 (VV116) Favipiravir Placebo
Outcomes	Primary Progression of COVID‐19: percentage of the participants who have progression of COVID‐19, defined as progress to critical COVID‐19 or death from any cause, through Day 29 Secondary Adverse events (AEs) and serious adverse events (SAEs). Time frame: up to 29 days Progress, Death: percentage of participants who experience these events by Day 29 Progress to critical COVID‐19 Death from any cause WHO 11‐point ordinal outcome scale: change in the WHO 11‐point ordinal outcome scale from baseline to Days 3, 5, 7, 10 and 29 (0 = uninfected, 10 = dead). Time frame: Days 3, 5, 7, 10 and 29 Change in chest CT scan (percentage of lung involved) from baseline to Days 7 and 10 SARS‐CoV‐2 clearance: percentage of participants who achieve SARS‐CoV‐2 clearance at Days 3, 5,7 and 10 Other outcome measures: SARS‐CoV‐2 viral genetic variation. Time frame: Day 1
Starting date	14 March 2022
Contact information	Juan Ma, Master Shanghai Junshi Bioscience Co., Ltd
Notes